BRPI0916555A2 - uso de opióides ou miméticos opióides para o tratamento de pacientes com câncer resistente - Google Patents
uso de opióides ou miméticos opióides para o tratamento de pacientes com câncer resistenteInfo
- Publication number
- BRPI0916555A2 BRPI0916555A2 BRPI0916555A BRPI0916555A BRPI0916555A2 BR PI0916555 A2 BRPI0916555 A2 BR PI0916555A2 BR PI0916555 A BRPI0916555 A BR PI0916555A BR PI0916555 A BRPI0916555 A BR PI0916555A BR PI0916555 A2 BRPI0916555 A2 BR PI0916555A2
- Authority
- BR
- Brazil
- Prior art keywords
- opioids
- cancer patients
- resistant cancer
- treat resistant
- opioid mimetics
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08013417.7 | 2008-07-31 | ||
| EP08013741.7A EP2149372B1 (en) | 2008-07-31 | 2008-07-31 | Use of opioids of the methadone group for the treatment of resistant cancer patients |
| PCT/EP2009/000584 WO2010012319A1 (en) | 2008-07-31 | 2009-01-29 | Use of opioids or opioid mimetics for the treatment of resistant cancer patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0916555A2 true BRPI0916555A2 (pt) | 2015-11-10 |
| BRPI0916555B1 BRPI0916555B1 (pt) | 2021-06-29 |
Family
ID=40011012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0916555-0A BRPI0916555B1 (pt) | 2008-07-31 | 2009-01-29 | Usos de opioides ou miméticos de opioides para tratamento de pacientes com câncer resistente, e combinação farmacêutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8901175B2 (pt) |
| EP (2) | EP2149372B1 (pt) |
| JP (1) | JP5804945B2 (pt) |
| CN (1) | CN102159212B (pt) |
| BR (1) | BRPI0916555B1 (pt) |
| CA (1) | CA2732497C (pt) |
| DK (2) | DK2149372T3 (pt) |
| ES (2) | ES2482168T3 (pt) |
| HU (1) | HUE031337T2 (pt) |
| PL (2) | PL2149372T3 (pt) |
| PT (2) | PT2149372E (pt) |
| RU (1) | RU2520636C2 (pt) |
| WO (1) | WO2010012319A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011009020A2 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| PL2716291T3 (pl) | 2012-10-08 | 2020-06-15 | Universität Ulm | Połączenie opioidów i leków przeciwnowotworowych do leczenia nowotworów |
| AU2018351502B2 (en) * | 2017-10-20 | 2024-09-05 | Purdue Pharma L.P. | Pharmaceutical dosage forms |
| WO2019197015A1 (en) | 2018-04-09 | 2019-10-17 | Peter Truog | Composition comprising 4-phenylbutyric acid derivatives & opioids |
| CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
| WO2020239948A1 (en) | 2019-05-28 | 2020-12-03 | Isanas Ag | A CENTRALLY ACTING µ-OPIOID RECEPTOR AGONIST IN COMBINATION WITH A CURCUMINOID FOR USE IN THE TREATMENT OF A TUMOUR OF THE CENTRAL NERVOUS SYSTEM |
| CN115844869B (zh) * | 2022-12-19 | 2024-08-16 | 新乡医学院 | 莱菔硫烷在逆转耐阿糖胞苷白血病细胞耐药性中的应用和药物组合物 |
| CN116173212A (zh) * | 2023-02-07 | 2023-05-30 | 杭州添帆生物科技有限公司 | 阿片类药物在制备黑色素瘤治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173486A (en) * | 1991-08-26 | 1992-12-22 | Bristol-Myers Squibb Company | Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents |
| ES2440799T3 (es) * | 2005-05-13 | 2014-01-30 | Novartis Ag | Métodos para tratar cáncer resistente a los fármacos |
-
2008
- 2008-07-31 DK DK08013741.7T patent/DK2149372T3/da active
- 2008-07-31 PT PT80137417T patent/PT2149372E/pt unknown
- 2008-07-31 EP EP08013741.7A patent/EP2149372B1/en active Active
- 2008-07-31 ES ES08013741.7T patent/ES2482168T3/es active Active
- 2008-07-31 PL PL08013741T patent/PL2149372T3/pl unknown
-
2009
- 2009-01-29 PT PT97763486T patent/PT2320900T/pt unknown
- 2009-01-29 BR BRPI0916555-0A patent/BRPI0916555B1/pt active IP Right Grant
- 2009-01-29 DK DK09776348.6T patent/DK2320900T3/en active
- 2009-01-29 WO PCT/EP2009/000584 patent/WO2010012319A1/en active Application Filing
- 2009-01-29 EP EP09776348.6A patent/EP2320900B1/en active Active
- 2009-01-29 CN CN200980136278.9A patent/CN102159212B/zh active Active
- 2009-01-29 JP JP2011520333A patent/JP5804945B2/ja active Active
- 2009-01-29 CA CA2732497A patent/CA2732497C/en active Active
- 2009-01-29 US US13/056,918 patent/US8901175B2/en active Active
- 2009-01-29 HU HUE09776348A patent/HUE031337T2/hu unknown
- 2009-01-29 ES ES09776348.6T patent/ES2596363T3/es active Active
- 2009-01-29 PL PL09776348T patent/PL2320900T3/pl unknown
- 2009-01-29 RU RU2011107280/15A patent/RU2520636C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5804945B2 (ja) | 2015-11-04 |
| ES2482168T3 (es) | 2014-08-01 |
| RU2520636C2 (ru) | 2014-06-27 |
| DK2149372T3 (da) | 2014-07-07 |
| US8901175B2 (en) | 2014-12-02 |
| PT2149372E (pt) | 2014-07-25 |
| JP2011529454A (ja) | 2011-12-08 |
| EP2149372B1 (en) | 2014-04-02 |
| CA2732497A1 (en) | 2010-02-04 |
| WO2010012319A1 (en) | 2010-02-04 |
| CA2732497C (en) | 2017-01-17 |
| PT2320900T (pt) | 2016-10-13 |
| DK2320900T3 (en) | 2016-10-24 |
| ES2596363T3 (es) | 2017-01-09 |
| EP2320900A1 (en) | 2011-05-18 |
| HUE031337T2 (hu) | 2017-07-28 |
| US20110270011A1 (en) | 2011-11-03 |
| EP2149372A1 (en) | 2010-02-03 |
| CN102159212A (zh) | 2011-08-17 |
| EP2320900B1 (en) | 2016-07-06 |
| CN102159212B (zh) | 2015-09-16 |
| PL2149372T3 (pl) | 2015-03-31 |
| RU2011107280A (ru) | 2012-09-10 |
| BRPI0916555B1 (pt) | 2021-06-29 |
| PL2320900T3 (pl) | 2017-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1063I1 (fr) | Traitement combiné de tumeurs exprimant la cd38 | |
| BRPI0916555A2 (pt) | uso de opióides ou miméticos opióides para o tratamento de pacientes com câncer resistente | |
| BRPI0807487A2 (pt) | Uso de antagonistas de il-23 para o tratamento de infecção | |
| BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
| BR112012004281A2 (pt) | uso de metformina tratamento e prevenção de câncer | |
| BRPI0908127A2 (pt) | Método para o tratamento do câncer da próstata com degarelix antagonista do gnrh | |
| BRPI0821660A2 (pt) | Combinações de agentes terapêuticos para tratamento de câncer | |
| BRPI0920104A2 (pt) | tratamento de soluções ou de águas residuais | |
| BRPI0814624A2 (pt) | Tratamento de doença neurodegenerativa progresiva com ibudilaste | |
| FR2951637B1 (fr) | Table pour massages de personnes allongees ou assises. | |
| BRPI0719210A2 (pt) | Uso de compostos espiro-oxindol como agentes terapêuticos | |
| BRPI0821779A2 (pt) | tratamento terapêutico de câncer | |
| BRPI0819821A2 (pt) | Preparação e uso de polianilinas para tratamento de água | |
| BRPI0908428A2 (pt) | uso de ranozalina para tratar a dor. | |
| BRPI0912683A2 (pt) | tratamento de tumores metastáticos | |
| BRPI0910780A2 (pt) | uso de antagonistas de opióides para o tratamento da retenção urinária | |
| BR112013013898A2 (pt) | compostos de pirimidinona para o uso no tratamento de doenças ou condições mediadas por lp-pla2 | |
| BRPI1008566A2 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
| EP2049139A4 (en) | TREATMENT OF TUMORS EXPRESSING RAS | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| BRPI1008564A2 (pt) | métodos e composições para o dignóstico e tratamento de câncer | |
| BR112012005774B8 (pt) | uso de um inibidor de quinase antiangiogênico no tratamento de câncer | |
| BRPI0916043A2 (pt) | composição farmacêutica e alimento funcional para prevenir ou tratar câncer | |
| BRPI0810475A2 (pt) | uso de dimiracetam no tratamento de dor crônica | |
| BRPI0714318A2 (pt) | Utilização de 2-benzoil-imidazopiridinas em terapêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001 |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |